What's new

Treating people with cancer 2017-2021

The Treating people with cancer in Queensland and Victoria: National benchmarking starts here, 2017-2021 report has been developed by Queensland and Victoria and builds on analysis already happening in both states. This first of its kind report, includes 8 common cancers: brain, breast, colorectal, gynaecological, hepatobiliary, lung, prostate and upper gastrointestinal and focuses on treatment rates, time to first treatment, surgical mortality and survival.

This collaboration demonstrates the mutual benefit of identifying areas of improvement for cancer services and is an important tool for monitoring current investments in cancer care, tracking healthcare performance, striving towards best practices and improving outcomes for people with cancer.

CAQ Strategic Plan 2024-26

Our 2024-26 strategic plan outlines key strategies aimed at realising our goals of engagement, leadership and impact. We're committed to achieving measurable success and providing clear insights into how the healthcare system performs, to help improve cancer care delivery and patient outcomes for all Queenslanders with cancer.

This document outlines the vision, strategy and next steps in shaping the future of Cancer Alliance Queensland.

Rare Cancer Care & Research Fund

The Rare Cancer Care & Research Fund was established in October 2022 through the generosity and foresight of two patients of the Sunshine Coast Hospital and Health Service. In essence, the Fund helps provide patient-centred care and research initiatives that advance the provision of care for people with rare forms of cancer. Funds will not be applied to initiatives for those forms of cancer for which significant government and private funding is already available.

The Fund operates under the auspice of Wishlist (Sunshine Coast Health Foundation) in collaboration with Sunshine Coast University Hospital (SCUH), particularly the Medical Oncology Unit and the Research Governance and Development Unit. Collaborations are also in place with key external parties including Cancer Alliance Queensland and Australian Families 4 Genomics.

Queensland AML Quality Index 2012-2021

The Queensland Acute Myeloid Leukaemia Quality Index has been developed through extensive consultation with the Haematology Sub-committee, comprising of expert haematologists from across Queensland. This report is the first of its kind and aims to provide not only an epidemiological overview but also an analysis of key quality indicators. The retrospective data used in this Index is useful for benchmarking and establishing baseline AML treatment rates for Queensland.  The Index reports on 10 years of data from 2012-2021, and includes outcomes such as multidisciplinary team review, FLT3 testing, treatment patterns, 30-day mortality and survival.

Log in to our APPLICATIONS

  • some image


    Login to QOOL for access to current patient information

  • some image


    Login to QOOL-Dash to access MDT patient activity and clinical indicators information

  • some image


    Login to OASys to access statistics about cancer in Queensland